Scarica l'app Stockscreener
194.90
0.66%
-1.30
Dopo l'orario di chiusura:
194.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$196.20
Aprire:
$196.59
Volume 24 ore:
1.24M
Relative Volume:
1.39
Capitalizzazione di mercato:
$21.57B
Reddito:
$11.28B
Utile/perdita netta:
$1.07B
Rapporto P/E:
21.50
EPS:
9.0657
Flusso di cassa netto:
$1.33B
1 W Prestazione:
-0.16%
1M Prestazione:
+2.95%
6M Prestazione:
+3.02%
1 anno Prestazione:
+13.31%
Intervallo 1D:
$194.29
$197.38
Intervallo di 1 settimana:
$192.35
$197.38
Portata 52W:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
194.90 | 21.72B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
492.51 | 181.06B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
182.67 | 127.84B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.53 | 44.81B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.53 | 38.21B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
383.57 | 36.00B | 3.77B | 449.25M | 240.68M | 7.8556 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
DGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year? - Yahoo Finance
Quest Diagnostics Stock: Analyst Estimates & Ratings - Yahoo Finance
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting - Investing.com India
Quest Diagnostics 8-K SEC Filing May 2026: Shareholder Vote Results and Company Information - Minichart
Quest Diagnostics (DGX) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Quest Diagnostics (DGX) director granted 1,142 restricted stock units in Form 4 filing - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 RSUs - Stock Titan
Quest Diagnostics (DGX) director receives 1,142-share restricted stock unit grant - Stock Titan
Quest Diagnostics (DGX) director gets 1,142-share restricted stock unit award - Stock Titan
Director Tracey Doi of Quest Diagnostics (DGX) receives 1,142-share equity award - Stock Titan
Director at Quest Diagnostics (DGX) awarded 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 stock units - Stock Titan
Quest Diagnostics (DGX) director receives 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (DGX) receives 1,142 share units - Stock Titan
Quest Diagnostics (NYSE: DGX) details 2026 shareholder votes on board, pay and auditor - Stock Titan
Why is Quest Diagnostics (DGX) down 5% since last earnings report? - MSN
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report? - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Keeps Quarterly Dividend at $0.86 a Share, Payable July 22 to Holders of Record July 8 - marketscreener.com
Quest Diagnostics Declares Quarterly Cash Dividend - Barchart.com
Guardant Health’s Shield Blood-Based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - Nevada Business Magazine
Is This the Right Time to Hold DGX Stock in Your Portfolio? - TradingView
$0.86 a share: Quest Diagnostics dividend hits investors in July - Stock Titan
Quest Diagnostics Incorporated announces Quarterly dividend, payable on July 22, 2026 - marketscreener.com
Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating - Moomoo
Quest Diagnostics (NYSE:DGX): A Solid Dividend Play Backed by Strong Profitability and Financial Health - ChartMill
International Assets Investment Management LLC Purchases New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Q2 EPS Estimates for Quest Diagnostics Cut by Zacks Research - MarketBeat
173,262 Shares in Quest Diagnostics Incorporated $DGX Bought by Conning Inc. - MarketBeat
How The Investment Narrative For Quest Diagnostics (DGX) Is Shifting With New Valuation Work - Yahoo Finance
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics Incorporated $DGX Shares Acquired by Ethic Inc. - MarketBeat
Truist Financial Corp Cuts Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Swedbank AB Increases Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Generali Asset Management SPA SGR Purchases 8,924 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics (NYSE: DGX) sells $500M in 5.000% senior notes due 2036 - Stock Titan
Bullish Quarterly Results: 3 Companies Raising Guidance - TradingView
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term - Yahoo Finance
DGX SEC FilingsQuest Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
DGX6380050 Bond Analysis — Key Metrics - TradingView
Quest Diagnostics Incorporated $DGX Shares Sold by Keybank National Association OH - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Acquired by Davis Selected Advisers - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Holdings Increased by Artemis Investment Management LLP - MarketBeat
Quest Diagnostics | 8-K: Current report - Moomoo
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):